Tissue Kallikrein 1-Based Formulations for Agricultural and Environmental Applications

Publication ID: 24-11857608_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Tissue Kallikrein 1-Based Formulations for Agricultural and Environmental Applications,” Published Technical Disclosure No. 24-11857608_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857608_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,608.

Summary of the Inventive Concept

This inventive concept leverages the core technology of tissue kallikrein 1 (KLK1) polypeptides to develop innovative solutions for agricultural and environmental challenges, including crop growth enhancement, soil erosion prevention, wildfire prevention, and water quality improvement.

Background and Problem Solved

The original patent disclosed dosage forms of tissue kallikrein 1 for treating ischemic conditions. However, the limitations of this technology in addressing agricultural and environmental issues prompted the development of new applications and use cases. The inventive concept addresses the need for sustainable and effective solutions in these fields.

Detailed Description of the Inventive Concept

The new claims describe systems, methods, and compositions that utilize KLK1-based formulations to enhance plant growth and stress resistance, reduce soil erosion, predict and prevent wildfires, and improve water quality. These formulations can be administered through various means, including subcutaneous or intravenous injection, and can be monitored using sensor systems. The KLK1 polypeptides interact with plant cells to stimulate growth and increase resistance to environmental stressors, while also reducing vegetation water content to prevent wildfires.

Novelty and Inventive Step

The new claims introduce a paradigm shift in the application of KLK1 technology, moving from ischemic condition treatment to agricultural and environmental solutions. The inventive step lies in the recognition of KLK1's potential in these new fields and the development of formulations and systems that effectively address specific challenges.

Alternative Embodiments and Variations

Alternative embodiments may include different KLK1 polypeptide formulations, varying administration methods, and diverse sensor systems for monitoring crop growth and stress levels. Variations may also involve integrating KLK1 technology with existing agricultural and environmental practices to create hybrid solutions.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the agricultural and environmental industries, with potential applications in crop enhancement, soil conservation, wildfire prevention, and water quality management. The target market includes agricultural companies, environmental organizations, and government agencies seeking sustainable and effective solutions to pressing challenges.

CPC Classifications

SectionClassGroup
A A61 A61K38/4853
A A61 A61K9/0019
A A61 A61K45/06
C C12 C12Y304/21035

Field of Art

Biotechnology and pharmaceutical formulations, specifically protein-based therapeutic and agricultural compositions, with expertise in polypeptide delivery systems and biological interactions

Person of Ordinary Skill (PHOSITA) Profile

A professional with advanced degrees in biotechnology, biochemistry, or chemical engineering, having knowledge of protein engineering, drug delivery mechanisms, and cross-disciplinary applications of biological molecules

Obviousness Rationale

A PHOSITA would recognize the inherent versatility of KLK1 polypeptides based on the source patent's detailed characterization of protein interactions and delivery mechanisms. The agricultural and environmental applications represent a predictable extension of the protein's known biological properties, utilizing established biotechnological techniques for repurposing therapeutic molecules. The sensor-based monitoring and varied administration methods are consistent with standard biotechnological approaches to developing multi-functional biological systems.

Obvious Combinations & Variations

Source Patent Element
Subcutaneous and intravenous administration of KLK1 polypeptides for treating ischemic conditions
PTD Variation
Applying KLK1 formulations to agricultural and environmental applications with similar delivery mechanisms
Obviousness Reasoning
Known protein delivery techniques can be readily adapted across biological systems, representing a predictable variation within biotechnological design principles
Source Patent Element
Precise serum level monitoring of KLK1 polypeptides
PTD Variation
Using sensor systems to monitor crop growth and stress levels with KLK1-based formulations
Obviousness Reasoning
Extending biological monitoring techniques from medical to agricultural contexts is a standard biotechnological approach with predictable implementation strategies
Source Patent Element
Specific formulation of KLK1 polypeptides for targeted biological interactions
PTD Variation
Creating KLK1-based polymers for soil stabilization and water quality improvement
Obviousness Reasoning
Modifying protein compositions for alternative functional applications represents a routine engineering design choice within protein biotechnology
Source Patent Element
Therapeutic targeting of specific biological conditions using KLK1 polypeptides
PTD Variation
Developing KLK1 formulations to reduce vegetation water content and prevent wildfires
Obviousness Reasoning
Identifying novel functional applications of known biological molecules through systematic exploration is an expected scientific methodology
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857608 and the disclosed variations, a person having ordinary skill in the art would find the agricultural and environmental applications of KLK1 polypeptides to be obvious extensions of the existing biotechnological knowledge. The systematic repurposing of therapeutic protein delivery mechanisms into novel domains represents a predictable innovation within the established biotechnological framework, thereby rendering potential claims in these areas unpatentable under 35 U.S.C. ยง 103.

Original Patent Information

Patent NumberUS 11,857,608
TitleDosage forms of tissue kallikrein 1
Assignee(s)DiaMedica Inc.